Loading…

Toward inclusive therapy with CFTR modulators: Progress and challenges

Cystic fibrosis is caused by gene mutations that result in an abnormal Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein on the surface of cells. CFTR modulators are a novel class of drugs that directly target the molecular defect. CFTR modulators include potentiators that result in...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric pulmonology 2017-11, Vol.52 (S48), p.S4-S14
Main Authors: Guimbellot, Jennifer, Sharma, Jyoti, Rowe, Steven M.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4483-946bd58aa9ba0110959172cb248dfa2365eb42bcd3dbd55d27321aa24b228d833
cites cdi_FETCH-LOGICAL-c4483-946bd58aa9ba0110959172cb248dfa2365eb42bcd3dbd55d27321aa24b228d833
container_end_page S14
container_issue S48
container_start_page S4
container_title Pediatric pulmonology
container_volume 52
creator Guimbellot, Jennifer
Sharma, Jyoti
Rowe, Steven M.
description Cystic fibrosis is caused by gene mutations that result in an abnormal Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein on the surface of cells. CFTR modulators are a novel class of drugs that directly target the molecular defect. CFTR modulators include potentiators that result in improved activity of the channel; correctors that help the protein traffic to the cell surface properly; and readthrough agents that restore full‐length CFTR by suppression of premature termination codons, among other novel classes more recently established. While some of these drugs, CFTR potentiators in particular, have provided remarkable improvements for CF patients, others have yet to achieve profoundly improved outcomes, and many CF patients are not yet impacted by CFTR modulators due to lack of knowledge regarding susceptibility of their mutations to treatment. One limitation to expanding these types of therapies to the maximum number of patients with CF is the lack of rigorously validated clinical biomarkers that can determine efficacy on an individual basis, as well as few pre‐clinical tools that can predict whether an individual with a rare combination of mutant alleles will respond to a particular CFTR modulator regimen. In this review, we discuss the various groups of CFTR modulators and their status in clinical development, as well as address the current literature on biomarkers, pre‐clinical cell‐based tools, and the role of pharmacometrics in creating therapeutic strategies to improve the lives of all patients with cystic fibrosis, regardless of their specific mutation.
doi_str_mv 10.1002/ppul.23773
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6208153</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1959237502</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4483-946bd58aa9ba0110959172cb248dfa2365eb42bcd3dbd55d27321aa24b228d833</originalsourceid><addsrcrecordid>eNp90U9LwzAYBvAgipvTix9ACl5E6Myfpk08CDKcCgOHbOeQNtnWkTU1aR379mZOh3rwlMP74-F98wBwjmAfQYhv6ro1fUyyjByALoKcxzDh6SHosozSOGUp6YAT75cQhhlHx6CDGWMBZl0wnNi1dCoqq8K0vnzXUbPQTtabaF02i2gwnLxGK6taIxvr_G00dnbutPeRrFRULKQxupprfwqOZtJ4ffb19sB0-DAZPMWjl8fnwf0oLpKEkZgnaa4ok5LnEqKwAeUow0WOE6ZmEpOU6jzBeaGICo4qnBGMpMRJjjFTjJAeuNvl1m2-0qrQVeOkEbUrV9JthJWl-D2pyoWY23eRYsgQ3QZcfQU4-9Zq34hV6QttjKy0bb1AnGQUJ5DBQC__0KVtXRXOC4ry8OEU4qCud6pw1nunZ_tlEBTbesS2HvFZT8AXP9ff0-8-AkA7sC6N3vwTJcbj6WgX-gFAxpsv</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1959237502</pqid></control><display><type>article</type><title>Toward inclusive therapy with CFTR modulators: Progress and challenges</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>Guimbellot, Jennifer ; Sharma, Jyoti ; Rowe, Steven M.</creator><creatorcontrib>Guimbellot, Jennifer ; Sharma, Jyoti ; Rowe, Steven M.</creatorcontrib><description>Cystic fibrosis is caused by gene mutations that result in an abnormal Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein on the surface of cells. CFTR modulators are a novel class of drugs that directly target the molecular defect. CFTR modulators include potentiators that result in improved activity of the channel; correctors that help the protein traffic to the cell surface properly; and readthrough agents that restore full‐length CFTR by suppression of premature termination codons, among other novel classes more recently established. While some of these drugs, CFTR potentiators in particular, have provided remarkable improvements for CF patients, others have yet to achieve profoundly improved outcomes, and many CF patients are not yet impacted by CFTR modulators due to lack of knowledge regarding susceptibility of their mutations to treatment. One limitation to expanding these types of therapies to the maximum number of patients with CF is the lack of rigorously validated clinical biomarkers that can determine efficacy on an individual basis, as well as few pre‐clinical tools that can predict whether an individual with a rare combination of mutant alleles will respond to a particular CFTR modulator regimen. In this review, we discuss the various groups of CFTR modulators and their status in clinical development, as well as address the current literature on biomarkers, pre‐clinical cell‐based tools, and the role of pharmacometrics in creating therapeutic strategies to improve the lives of all patients with cystic fibrosis, regardless of their specific mutation.</description><identifier>ISSN: 8755-6863</identifier><identifier>EISSN: 1099-0496</identifier><identifier>DOI: 10.1002/ppul.23773</identifier><identifier>PMID: 28881097</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Biomarkers ; clinical trials ; Cystic fibrosis ; cystic fibrosis (CF) ; Cystic Fibrosis - drug therapy ; Cystic Fibrosis - metabolism ; Cystic Fibrosis Transmembrane Conductance Regulator - metabolism ; Humans ; Molecular Targeted Therapy ; Mutation ; pharmacology</subject><ispartof>Pediatric pulmonology, 2017-11, Vol.52 (S48), p.S4-S14</ispartof><rights>2017 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4483-946bd58aa9ba0110959172cb248dfa2365eb42bcd3dbd55d27321aa24b228d833</citedby><cites>FETCH-LOGICAL-c4483-946bd58aa9ba0110959172cb248dfa2365eb42bcd3dbd55d27321aa24b228d833</cites><orcidid>0000-0002-0514-8536 ; 0000-0001-9045-0133</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28881097$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Guimbellot, Jennifer</creatorcontrib><creatorcontrib>Sharma, Jyoti</creatorcontrib><creatorcontrib>Rowe, Steven M.</creatorcontrib><title>Toward inclusive therapy with CFTR modulators: Progress and challenges</title><title>Pediatric pulmonology</title><addtitle>Pediatr Pulmonol</addtitle><description>Cystic fibrosis is caused by gene mutations that result in an abnormal Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein on the surface of cells. CFTR modulators are a novel class of drugs that directly target the molecular defect. CFTR modulators include potentiators that result in improved activity of the channel; correctors that help the protein traffic to the cell surface properly; and readthrough agents that restore full‐length CFTR by suppression of premature termination codons, among other novel classes more recently established. While some of these drugs, CFTR potentiators in particular, have provided remarkable improvements for CF patients, others have yet to achieve profoundly improved outcomes, and many CF patients are not yet impacted by CFTR modulators due to lack of knowledge regarding susceptibility of their mutations to treatment. One limitation to expanding these types of therapies to the maximum number of patients with CF is the lack of rigorously validated clinical biomarkers that can determine efficacy on an individual basis, as well as few pre‐clinical tools that can predict whether an individual with a rare combination of mutant alleles will respond to a particular CFTR modulator regimen. In this review, we discuss the various groups of CFTR modulators and their status in clinical development, as well as address the current literature on biomarkers, pre‐clinical cell‐based tools, and the role of pharmacometrics in creating therapeutic strategies to improve the lives of all patients with cystic fibrosis, regardless of their specific mutation.</description><subject>Biomarkers</subject><subject>clinical trials</subject><subject>Cystic fibrosis</subject><subject>cystic fibrosis (CF)</subject><subject>Cystic Fibrosis - drug therapy</subject><subject>Cystic Fibrosis - metabolism</subject><subject>Cystic Fibrosis Transmembrane Conductance Regulator - metabolism</subject><subject>Humans</subject><subject>Molecular Targeted Therapy</subject><subject>Mutation</subject><subject>pharmacology</subject><issn>8755-6863</issn><issn>1099-0496</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp90U9LwzAYBvAgipvTix9ACl5E6Myfpk08CDKcCgOHbOeQNtnWkTU1aR379mZOh3rwlMP74-F98wBwjmAfQYhv6ro1fUyyjByALoKcxzDh6SHosozSOGUp6YAT75cQhhlHx6CDGWMBZl0wnNi1dCoqq8K0vnzXUbPQTtabaF02i2gwnLxGK6taIxvr_G00dnbutPeRrFRULKQxupprfwqOZtJ4ffb19sB0-DAZPMWjl8fnwf0oLpKEkZgnaa4ok5LnEqKwAeUow0WOE6ZmEpOU6jzBeaGICo4qnBGMpMRJjjFTjJAeuNvl1m2-0qrQVeOkEbUrV9JthJWl-D2pyoWY23eRYsgQ3QZcfQU4-9Zq34hV6QttjKy0bb1AnGQUJ5DBQC__0KVtXRXOC4ry8OEU4qCud6pw1nunZ_tlEBTbesS2HvFZT8AXP9ff0-8-AkA7sC6N3vwTJcbj6WgX-gFAxpsv</recordid><startdate>201711</startdate><enddate>201711</enddate><creator>Guimbellot, Jennifer</creator><creator>Sharma, Jyoti</creator><creator>Rowe, Steven M.</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-0514-8536</orcidid><orcidid>https://orcid.org/0000-0001-9045-0133</orcidid></search><sort><creationdate>201711</creationdate><title>Toward inclusive therapy with CFTR modulators: Progress and challenges</title><author>Guimbellot, Jennifer ; Sharma, Jyoti ; Rowe, Steven M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4483-946bd58aa9ba0110959172cb248dfa2365eb42bcd3dbd55d27321aa24b228d833</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Biomarkers</topic><topic>clinical trials</topic><topic>Cystic fibrosis</topic><topic>cystic fibrosis (CF)</topic><topic>Cystic Fibrosis - drug therapy</topic><topic>Cystic Fibrosis - metabolism</topic><topic>Cystic Fibrosis Transmembrane Conductance Regulator - metabolism</topic><topic>Humans</topic><topic>Molecular Targeted Therapy</topic><topic>Mutation</topic><topic>pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Guimbellot, Jennifer</creatorcontrib><creatorcontrib>Sharma, Jyoti</creatorcontrib><creatorcontrib>Rowe, Steven M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Pediatric pulmonology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Guimbellot, Jennifer</au><au>Sharma, Jyoti</au><au>Rowe, Steven M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Toward inclusive therapy with CFTR modulators: Progress and challenges</atitle><jtitle>Pediatric pulmonology</jtitle><addtitle>Pediatr Pulmonol</addtitle><date>2017-11</date><risdate>2017</risdate><volume>52</volume><issue>S48</issue><spage>S4</spage><epage>S14</epage><pages>S4-S14</pages><issn>8755-6863</issn><eissn>1099-0496</eissn><abstract>Cystic fibrosis is caused by gene mutations that result in an abnormal Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein on the surface of cells. CFTR modulators are a novel class of drugs that directly target the molecular defect. CFTR modulators include potentiators that result in improved activity of the channel; correctors that help the protein traffic to the cell surface properly; and readthrough agents that restore full‐length CFTR by suppression of premature termination codons, among other novel classes more recently established. While some of these drugs, CFTR potentiators in particular, have provided remarkable improvements for CF patients, others have yet to achieve profoundly improved outcomes, and many CF patients are not yet impacted by CFTR modulators due to lack of knowledge regarding susceptibility of their mutations to treatment. One limitation to expanding these types of therapies to the maximum number of patients with CF is the lack of rigorously validated clinical biomarkers that can determine efficacy on an individual basis, as well as few pre‐clinical tools that can predict whether an individual with a rare combination of mutant alleles will respond to a particular CFTR modulator regimen. In this review, we discuss the various groups of CFTR modulators and their status in clinical development, as well as address the current literature on biomarkers, pre‐clinical cell‐based tools, and the role of pharmacometrics in creating therapeutic strategies to improve the lives of all patients with cystic fibrosis, regardless of their specific mutation.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>28881097</pmid><doi>10.1002/ppul.23773</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-0514-8536</orcidid><orcidid>https://orcid.org/0000-0001-9045-0133</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 8755-6863
ispartof Pediatric pulmonology, 2017-11, Vol.52 (S48), p.S4-S14
issn 8755-6863
1099-0496
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6208153
source Wiley-Blackwell Read & Publish Collection
subjects Biomarkers
clinical trials
Cystic fibrosis
cystic fibrosis (CF)
Cystic Fibrosis - drug therapy
Cystic Fibrosis - metabolism
Cystic Fibrosis Transmembrane Conductance Regulator - metabolism
Humans
Molecular Targeted Therapy
Mutation
pharmacology
title Toward inclusive therapy with CFTR modulators: Progress and challenges
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T02%3A58%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Toward%20inclusive%20therapy%20with%20CFTR%20modulators:%20Progress%20and%20challenges&rft.jtitle=Pediatric%20pulmonology&rft.au=Guimbellot,%20Jennifer&rft.date=2017-11&rft.volume=52&rft.issue=S48&rft.spage=S4&rft.epage=S14&rft.pages=S4-S14&rft.issn=8755-6863&rft.eissn=1099-0496&rft_id=info:doi/10.1002/ppul.23773&rft_dat=%3Cproquest_pubme%3E1959237502%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4483-946bd58aa9ba0110959172cb248dfa2365eb42bcd3dbd55d27321aa24b228d833%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1959237502&rft_id=info:pmid/28881097&rfr_iscdi=true